ETBI On Other Exchanges
Symbol
Exchange
OTC US

eastgate biotech corp (ETBI) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
--
EPS TTM
--
Shares Outstanding
--
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for EASTGATE BIOTECH CORP (ETBI)
\

Related News

No related news articles were found.

eastgate biotech corp (ETBI) Related Businessweek News

No Related Businessweek News Found

eastgate biotech corp (ETBI) Details

Eastgate Biotech Corp., a development stage company, develops novel formulations of natural compounds and pharmaceutical products. The company is developing pharmaceutical products, such as Lorazepam oral spray for acute seizures emergency treatment; Ketoconazole 2% topical ointment for treatment of skin fungal infections; and Metformin chewable/ sublingual tablets for treatment of type 2 diabetes. It is also developing natural products and dietary supplements, including E-drops Nano and PURALEN that are self-nanoemulsifying compositions containing natural essential oils for oral administration; Glucora, a soft gelatin capsule with Banaba extract in self-emulsifying formulation for oral administration; URBAN POWER, a soft gelatin capsule with Ursolic acid and Banaba extract in self-emulsifying formulation for oral administration; Vitamin D3 nanoemulsion, a nanoemulsion with cholecalciferol; and Cleanezze, a hand sanitizer containing oil. The company was formerly known as Eastgate Acquisitions Corporation and changed its name to Eastgate Biotech Corp. in December 2014. Eastgate Biotech Corp. was founded in 1999 and is based in North York, Canada.

2 Employees
Last Reported Date: 03/1/18
Founded in 1999

eastgate biotech corp (ETBI) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

eastgate biotech corp
Eastgate Biotech Announces Preparation to Initiate Phase III Clinical Trials on Insugin

EastGate Biotech Corp. announced its plans to take the next steps to initiate Phase III of its innovative liquid insulin mouth rinse solution, Insugin, for Type 2 diabetes patients in Pakistan. The Phase III study will be a multicenter, randomised, double-blind, placebo-controlled, parallel group study. After appropriate screening, approximately 200 male and female patients from up to 10 study centers will be treated in this study. Patients with Type 2 diabetes mellitus who are being treated by diet, exercise, untreated with antidiabetic medications or treated with and Metforrmin monotherapy or in combination with one other antidiabetic drug (excluding insulin) will be eligible for enrollment. Earlier, Insugin had met its primary endpoints in the Phase II clinical study in Pakistan demonstrating glucose management and lowering of 90-day HbA1c levels. The Phase II studies were completed in Pakistan by the company’s Joint Venture Partner, Genome Pharma/Origin Pharma. The JV partner will continue to be responsible for providing support, both in financial terms and operational activities, to conduct and carry out the Phase III studies in Pakistan.

EastGate Biotech Announces Positive Phase II Clinical Results of its Innovative Liquid Insulin Mouth Rinse Solution for Type 2 Diabetes

EastGate Biotech Corp. announced positive Phase II Clinical Results of its innovative liquid insulin mouth rinse solution for Type 2 diabetes patients. The 90-day Phase II clinical study was conducted in Pakistan at the Sharif Medical City Hospital. Dr. Ayub Latif Khawaja is the Principal Investigator (PI). This ongoing Phase II human clinical trial is estimated to enroll 50 Type 2 patients currently on metformin treatment. Interim results are based on the first 30 patients who took a regiment of 25 IU of Insugin, a recombinant human liquid insulin mouth rinse twice a day at mealtime along with 500 mg of Metformin. The Phase II study assessed safety, tolerability, pharmacokinetics and efficacy. A placebo arm was also incorporated in the clinical protocol. The study summary and conclusions included: Insugin offers unique benefits and the product’s goal is to slow down progression of Type 2 diabetes mellitus and reduce complications; Insugin displayed a good safety and tolerability profile; Observed a statistically significant decrease in A1c levels after 1 week of treatment in combination with Metformin versus placebo; Observed that the most significant HbA1c reduction resulted from administration of a single dose of Insugin (25 IU) two times a day; Observed improvements in insulin secretion in Type 2 diabetes patients during hyperglycemic clamp; Observed that clinical efficacy of Insugin was non-inferior to Metformin, while its effect on HOMA-IR and fasting insulin level was superior compared to Metformin; Prevents the first step of apoptotic cascade (cytochrome C release) and protects cells from dying when submitted to an oxidative stress level (high glucose levels); Prevents endothelial dysfunction, which is well correlated to an improvement of atherosclerosis and cardiovascular complications; Preserves beta cell mass and beta cell function over time, leading to a potential delay of the disease’s progression.

Eastgate Biotech Corp. Reports Earnings Results for the Third Quarter Ended September 30, 2017

Eastgate Biotech Corp. announced earnings results for the third quarter ended September 30, 2017. For the third quarter, the company announced sales was USD 23,138 compared to USD 0 a year ago. Operating loss was USD 1.690 million compared to USD 433,522 a year ago. Net loss was USD 1.632 million compared to USD 473,300 a year ago. Basic eps - continuing operations was USD 0 compared to basic loss per share from continuing operations of USD 0.002 a year ago. For the nine months, sales was USD 137,638 compared to USD 0 a year ago. Operating loss was USD 3.052 million compared to USD 2.291 million a year ago. Net loss was USD 3.249 million compared to USD 2.408 million a year ago. Basic loss per share from continuing operations was USD 0.01 compared to USD 0.01 a year ago.

 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

ETBI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ETBI.
View Industry Companies
 

Industry Analysis

ETBI

Industry Average

Valuation ETBI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 49.3x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 68.8x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact EASTGATE BIOTECH CORP, please visit www.EastGateBiotech.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.